Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: RNA sequencing of MEN1-WT and MEN1-KO NCI-H460 cells

PROVIDER: PRJNA888457 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21849070_1.fastq.gz	Fastqsanger.gz
	SRR21849070_2.fastq.gz	Fastqsanger.gz
	SRR21849071_1.fastq.gz	Fastqsanger.gz
	SRR21849071_2.fastq.gz	Fastqsanger.gz
	SRR21849072_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Project description:RIP-seq data from MEN1-WT and MEN1-KO NCI-H460 cells

| PRJNA1111658 | ENA

Differential expression of genes after transfection of STAT6 specific siRNA in NCI-H460 cells

Project description:The experiment was designed to identify the genes which get altered after the transfection of siRNA targeting STAT6 in NCI-H460 cells. The NCI-H460 cells plated in 12-well plate were transfected with 60nM of STAT6 specific siRNA. Biological duplicates of 2 samples were used viz. control NCI-H460 cells (Contol), NCI-H460 cells transfected with siRNA (siRNA)

2011-12-01 | E-GEOD-25942 | biostudies-arrayexpress

Project description:RNA sequencing of Men1-WT and Men1-KO mouse lung tissues

| PRJNA888804 | ENA

Homo sapiens

Project description:NCI-H460-LNM35 vs NCI-H460-N15

| PRJNA116235 | ENA

Differential expression of genes after transfection of STAT6 specific siRNA in NCI-H460 cells

2011-12-01 | GSE25942 | GEO

Differentially regulated genes in adipocytes derived from Men1-null vs WT mouse embryonic stem cells

Project description:MEN1 is a tumor suppressor gene loss of which causes lipoma (fatty tumors under the skin) and many other endocrine and non-endocrine tumors. It's target genes in fat cells (adipocytes) are unknown. Gene expression in adipocytes that were in vitro differentiated from mouse embryonic stem cells (mESCs) of Men1-nul l(Men1-KO) and WT mice were compared to assess the expression of genes upon menin loss in adipocytes that could lead to the deveopment of lipoma. mESCs (Men1-null and WT) were in vitro differentaited into adipocytes. Positive oil red O staining indicated successful differentiation into adipocytes. The cells were processed for RNA isolation. RNA preps were used for microarray analysis.

2016-02-03 | E-GEOD-65859 | biostudies-arrayexpress

The HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR mutated and wildtype NSCLC cells

Project description:The receptor tyrosine kinase (RTK) EGFR is overexpressed and mutated in NSCLC. These mutations can be targeted by RTK inhibitors (TKIs), such as erlotinib. Chromatin-modifying agents offer a novel therapy approach by sensitizing tumor cells to TKIs. The NSCLC cell lines HCC827 (EGFR mutant, adenocarcinoma), A549 (EGFR wt, adenocarcinoma) and NCI-H460 (EGFR wt, large cell carcinoma) were analyzed by SNP6.0 array. Changes in proliferation were quantified by WST-1 assay, apoptosis by Annexin V/7-AAD flow cytometry and histone marks (acH3, H3K4me1,-2,-3) by immunoblotting. Expectedly, the EGFR wt cell lines A549 and NCI-H460 were insensitive to the growth-inhibiting effect of single-agent erlotinib (IC50 70-100µM), compared to HCC827 (IC50 <0.02μM). Treatment with panobinostat diminished growth to <50% in both EGFR wt and <30% in HCC827 cells. The combination of both drugs significantly reduced proliferation by ≥70% in A549, >95% in HCC827, but not further in NCI-H460. Panobinostat alone induced differentiation and expression of p21WAF1/CIP1 and p53 in all three cell lines, with almost no further increase when combined with erlotinib. In contrast, combination treatment additively decreased pERK, pAKT and pEGFR in A549, and synergistically induced acH3 in both adenocarcinoma lines. Surprisingly, we also saw an induction of H3K4 methylation marks in all three cell lines. In conclusion, panobinostat synergistically sensitized lung adenocarcinoma cells to the antiproliferative effects of erlotinib. Since single-agent erlotinib has only modest clinical effects in adenocarcinoma EGFR wt patients, combination therapy with an HDACi might offer a promising therapy approach to extend this activity. Copy-number analysis of three NSCLC cell lines HCC827, A549 and NCI-H460 (in unicates) was performed according to protocol by Affymetrix Genome-Wide Human SNP-Array 6.0.

2014-12-03 | E-GEOD-63784 | biostudies-arrayexpress

AgTU: TPP for target ID of AgTU for revealing its anticancer mechinary

Project description:TPP: thermal proteome profiling of AgTU in HeLa and NCI-H460 cells

2024-03-17 | PXD042400 | Pride

Comparative expression of bone metastasis clones and its parental cells on Chinese lung adenocarcinoma cell line SPC-A-1 and human larger cell lung cancer cell line NCI-H460 by cDNA array.

Project description:Chinese lung adenocarcinoma cancer cells (SPC-A-1) and human larger cell lung cancer cells (NCI-H460) were injected into left cardiac ventricle of nude mice for bone metastases model, respectively. Bone metastatic lesions were detected by bone scintigraphy with 99mTc-methylene diphophonate, removed bone metastatic lesions for cell primary culture, chromosome analysis for determine the bone metastatic cells have a characterization of unchanged humanization, in the anesthesia death mice. Through eight in vivo ~ in vitro selections, the 4th, 8th generation cells of SPC-A-1, 8th generation cells of NCI-H460 and their parental cells were used for microarray analysis, respectively. Bone metastatic clones 4th and/or 8th generation SPC-A-1 vs. SPC-A-1, 8th generation NCI-H460 vs. NCI-H460, respectively. Biological replicates: one replicate for every group, independently grown and harvested. One replicate per array.

2017-05-01 | E-GEOD-57402 | biostudies-arrayexpress

NCI-H460-LNM35 vs NCI-H460-N15

Project description:Comparing genome-wide gene expression profiles of highly metastatic lung cancer cell line NCI-H460-LNM35 vs low metastatic parental clone NCI-H460-N15 Keywords: Expression profiling with cDNA microarray

2010-08-21 | GSE16649 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data